NCT06885905

Brief Summary

To develop and validate a novel disease-specific questionnaire for measuring HRQoL in patients with Chronic Pulmonary Aspergillosis (CPA-HAQ) for use in clinical research, including clinical trials.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2024

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 27, 2024

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

March 13, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

March 20, 2025

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 23, 2025

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 23, 2026

Completed
Last Updated

March 20, 2025

Status Verified

March 1, 2025

Enrollment Period

9 months

First QC Date

March 13, 2025

Last Update Submit

March 13, 2025

Conditions

Chronic Pulmonary Aspergillosis

Keywords

CPA

Outcome Measures

Primary Outcomes (1)

  • Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.

    To develop and validate a novel disease-specific health-related quality of life (HRQoL) measure in chronic pulmonary aspergillosis (CPA): The Chronic Pulmonary Aspergillosis Health Assessment Questionnaire (CPA-HAQ)

    30 months

Secondary Outcomes (2)

  • Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.

    30 months

  • Impact of Chronic Pulmonary Aspergillosis (CPA) on health status and Well-being.

    30 months

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Individuals with confirmed Chronic Pulmonary Aspergillosis

You may qualify if:

  • All patients \>/= 18 years old and able to provide informed consent
  • Patients with a diagnosis of chronic pulmonary aspergillosis
  • To speak and understand English
  • Able to provide informed consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Ninewells Hospital & Medical School

Dundee, DD1 9SY, United Kingdom

RECRUITING

Imperial College London

London, United Kingdom

RECRUITING

Manchester NHS Foundation Trust

Manchester, United Kingdom

RECRUITING

Related Links

Biospecimen

Retention: SAMPLES WITH DNA

Blood and sputum

Central Study Contacts

Dareen Marghlani, MSc

CONTACT

dsm20@ic.ac.ukdsm20@ic.ac.uk

Anand Shah, PhD

CONTACT

s.anand@imperial.ac.uk

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 13, 2025

First Posted

March 20, 2025

Study Start

November 27, 2024

Primary Completion

August 23, 2025

Study Completion

April 23, 2026

Last Updated

March 20, 2025

Record last verified: 2025-03

Data Sharing

IPD Sharing
Will not share

Locations

GB(3)